While anti-vascular endothelial growth factor (VEGF) agents and laser therapy have been employed in treating choroidal neovascularization, the FDA (U.S. Food and Drug Administration) has not approved any treatment strategies for retinal atrophy [13]. This evidence concerns the gene VEGFA and choroidal neovascularization.